{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Liver+Carcinoma&page=4",
    "query": {
      "condition": "Primary Liver Carcinoma",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 287,
    "total_pages": 29,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Liver+Carcinoma&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Liver+Carcinoma&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T04:32:41.138Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00083213",
      "title": "Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "ziv-aflibercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 25,
      "start_date": "2004-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-06-03",
      "last_synced_at": "2026-10-08T04:32:41.138Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00083213"
    },
    {
      "nct_id": "NCT07285044",
      "title": "The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyloidosis",
        "Basal Cell Carcinoma",
        "Biliary Tract Carcinoma",
        "Bladder Carcinoma",
        "Breast Carcinoma",
        "Cervical Carcinoma",
        "Colorectal Carcinoma",
        "Endometrial Carcinoma",
        "Fallopian Tube Carcinoma",
        "Gastroesophageal Junction Carcinoma",
        "Glioblastoma",
        "Head and Neck Carcinoma",
        "Hematopoietic and Lymphatic System Neoplasm",
        "Hepatocellular Carcinoma",
        "Hodgkin Lymphoma",
        "Lung Carcinoma",
        "Malignant Solid Neoplasm",
        "Mantle Cell Lymphoma",
        "Melanoma",
        "Merkel Cell Carcinoma",
        "Multiple Myeloma",
        "Myelodysplastic Syndrome",
        "Ovarian Carcinoma",
        "Pancreatic Carcinoma",
        "Primary Peritoneal Carcinoma",
        "Prostate Carcinoma",
        "Renal Cell Carcinoma",
        "Squamous Cell Carcinoma",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cancer Therapeutic Procedure",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2025-12-18",
      "completion_date": "2027-05-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-08T04:32:41.138Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07285044"
    },
    {
      "nct_id": "NCT00746655",
      "title": "SBRT + TACE for Primary Hepatocellular Carcinoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Stereotactic Body Radiation Therapy (SBRT)",
          "type": "RADIATION"
        },
        {
          "name": "Transcatheter Arterial Chemoembolization (TACE)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2009-07",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2015-12-24",
      "last_synced_at": "2026-10-08T04:32:41.138Z",
      "location_count": 4,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00746655"
    },
    {
      "nct_id": "NCT02057874",
      "title": "3-Tesla MRI Response to TACE in HCC (Liver Cancer)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adult Primary Hepatocellular Carcinoma",
        "Advanced Adult Primary Liver Cancer",
        "Localized Resectable Adult Primary Liver Cancer",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Stage A Adult Primary Liver Cancer (BCLC)",
        "Stage B Adult Primary Liver Cancer (BCLC)"
      ],
      "interventions": [
        {
          "name": "3 Tesla Magnetic Resonance Imaging",
          "type": "DEVICE"
        },
        {
          "name": "Magnevist® (Intravenous (IV) administration of MRI contrast agent)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2014-02",
      "completion_date": "2015-12-04",
      "has_results": true,
      "last_update_posted_date": "2018-07-11",
      "last_synced_at": "2026-10-08T04:32:41.138Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02057874"
    },
    {
      "nct_id": "NCT01180959",
      "title": "Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2011-04-14",
      "completion_date": "2021-05-19",
      "has_results": true,
      "last_update_posted_date": "2022-11-07",
      "last_synced_at": "2026-10-08T04:32:41.138Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01180959"
    },
    {
      "nct_id": "NCT00085410",
      "title": "Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Extrahepatic Bile Duct",
        "Adenocarcinoma of the Gallbladder",
        "Advanced Adult Primary Liver Cancer",
        "Gastrointestinal Cancer",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Extrahepatic Bile Duct Cancer",
        "Recurrent Gallbladder Cancer",
        "Unresectable Extrahepatic Bile Duct Cancer",
        "Unresectable Gallbladder Cancer"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2004-01",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-08T04:32:41.138Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085410"
    },
    {
      "nct_id": "NCT01497444",
      "title": "Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Cancer",
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "hypoxia-activated prodrug TH-302",
          "type": "DRUG"
        },
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2012-05",
      "completion_date": "2019-11-01",
      "has_results": false,
      "last_update_posted_date": "2020-02-06",
      "last_synced_at": "2026-10-08T04:32:41.138Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01497444"
    },
    {
      "nct_id": "NCT00107536",
      "title": "Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Primary Hepatocellular Carcinoma",
        "Advanced Adult Primary Liver Cancer",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Extrahepatic Bile Duct Cancer",
        "Recurrent Gallbladder Cancer",
        "Unresectable Extrahepatic Bile Duct Cancer",
        "Unresectable Gallbladder Cancer"
      ],
      "interventions": [
        {
          "name": "lapatinib ditosylate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2005-10",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2015-04-29",
      "last_synced_at": "2026-10-08T04:32:41.138Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00107536"
    },
    {
      "nct_id": "NCT00003923",
      "title": "Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Extrahepatic Bile Duct Cancer",
        "Gallbladder Cancer",
        "Liver Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "porfimer sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "1999-03",
      "completion_date": "2002-02",
      "has_results": false,
      "last_update_posted_date": "2013-03-04",
      "last_synced_at": "2026-10-08T04:32:41.138Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003923"
    },
    {
      "nct_id": "NCT00427973",
      "title": "AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Primary Hepatocellular Carcinoma",
        "Advanced Adult Primary Liver Cancer",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Recurrent Adult Primary Liver Cancer"
      ],
      "interventions": [
        {
          "name": "cediranib maleate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "computed tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "dynamic contrast-enhanced magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2009-05",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2016-10-31",
      "last_synced_at": "2026-10-08T04:32:41.138Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00427973"
    }
  ]
}